Skip to search formSkip to main contentSkip to account menu

dolutegravir 25 MG Oral Tablet [Tivicay]

Known as: DOLUTEGRAVIR SODIUM 25 mg ORAL TABLET, FILM COATED [Tivicay], Tivicay 25 MG (as dolutegravir sodium) Oral Tablet, Tivicay 25 MG Oral Tablet 
National Institutes of Health

Related topics

Related topics

12 relations
MannitolOral TabletPolyethylene GlycolsPolyvinyl Alcohol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
De‐simplifying single‐tablet antiretroviral treatments: uptake, risks and cost savings
As more HIV‐positive individuals receive antiretroviral therapy (ART), payers are seeking options for covering these increased… 
2019
2019
Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 48 weeks
Abstract Introduction: Generic drugs are helpful to enhance the efficiency of the sanitary system. A generic coformulation of… 
2018
2018
Patient perspectives on de‐simplifying their single‐tablet co‐formulated antiretroviral therapy for societal cost savings
The incremental costs of expanding antiretroviral (ARV) drug treatment to all HIV‐infected patients are substantial, so cost… 
2018
2018
1ISG-003 Cost saving in antiretroviral therapy through breaking fixed-dose combination and switch to generic formulations
Background The commercialisation of fixed-dose combination meant an improvement in antiretroviral therapy (ART). With generics we… 
2018
2018
Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
Generic drugs may help to support antiretroviral treatment. We want to assess the efficacy and safety at 24 weeks of the change… 
2015
2015
Dolutegravir in HIV-1 infection: a guide to its use
Oral dolutegravir (Tivicay®) is a new-generation HIV-1 integrase strand transfer inhibitor approved as a component of… 
Review
2014
Review
2014
Dolutegravir: A Review of Its Use in the Management of HIV-1 Infection in Adolescents and Adults
Dolutegravir (Tivicay®) is a new-generation HIV-1 integrase strand transfer inhibitor recently approved in the EU and Japan for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)